Gain Therapeutics (NASDAQ:GANX) Stock, Quote.Headers.trade-ideas

GAIN THERAPEUTICS INC

Gain Therapeutics

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Parkinsons disease

Biotech

News

Health Care

Movers

General

GANX

Gain Therapeutics reported positive Phase 1 results for GT-02287, showing safety and tolerability across all age groups. The company plans a Parkinson&#39;s disease trial by Q4 2024.

Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson&#39;s Disease

wall street ai9

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

FOXO

IRON

SVMH

S&amp;P 500 Edges Lower; RH Shares Plunge After Q1 Results

movers image

ADBE

BAND

BIMI

CABA

CANF

CNSP

CORT

INAB

IONM

JFBR

KAVL

KITT

KYTX

LGVN

NAAS

NNVC

NVAX

OCUL

ONMD

PENN

POWW

RARE

RNXT

RZLT

THMO

TWOU

WLFC

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Gain Therapeutics Inc

Press Releases

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Earnings

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Biomea Fusion

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

Forte Biosciences

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

MAIA Biotechnology

Metagenomi

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PepGen

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Renovaro

Rein Therapeutics

Repare Therapeutics

Serina Therapeutics

Skye Bioscience

Surrozen

Shattuck Labs

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

HC Wainwright & Co.

Chardan Capital

Scotiabank

Roth MKM

Oppenheimer

Comments

Gain Therapeutics

Gain Therapeutics (NASDAQ:GANX) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell